Because the supply of pharmaceuticals to the population is significantly influenced by the assessment of the additional benefit, it makes sense to provide critical and careful support for the assessment process with a focus on identifying possible faults and counteracting imbalances.
The Interdisciplinary Platform on Benefit Assessment is a result of the discussion process between clinicians and experts, with the goal of supporting the benefit assessment in the form of interdisciplinary seminars.
The Interdisciplinary Platform on Benefit Assessment is a result of the discussion process between clinicians and experts, with the goal of supporting the benefit assessment in the form of interdisciplinary seminars.
- Interaction between HTA and authorisation
Volume 19, September 2024 - AMNOG 2.0: On the path to an efficient system
Volume 18, March 2024 - Impact of EU HTA on the AMNOG procedure
Volume 17, September 2023 - AMNOG: Financial stabilisation - new treatment paradigms
Volume 16, March 2023 - Further development of the AMNOG with a sense of proportion and evidence
Volume 15, September 2022 - Guidelines - their role in AMNOG and medical care
Volume 14, April 2022 - Patients and medical societies: Additional expertise for AMNOG
Volume 13, September 2021 - Digital health data: Benefits, costs, governance
Volume 12, March 2021 - European HTA Procedure: Advances and Pitfalls
Volume 11, September 2020 - What are the (additional) benefits of registry data?
Volume 10, April 2020 - Contextual evidence - Strategies for targeted therapy
Volume 9, October 2019 - European Benefit Assessment – Opportunities and Risks
Volume 8, April 2019 - Physician information via software: Orientation or control?
Volume 7, August 2018 - Physician information via software: Ways and goals
Volume 6, March 2018 - Evidence Gaps - what does Registry Data offer?
Volume 5, November 2017 - AMNOG 2.0 - Information Problems
Volume 4, April 2017 - Adaptative Pathways - Opportunities and Risks
Volume 3, September 2016 - Clinical studies - which endpoints count?
Volume 2, March 2016
- Zusammenspiel von HTA und Zulassung
Ausgabe 19, September 2024 - AMNOG 2.0: Auf dem Weg zu einem effizienten System
Ausgabe 18, März 2024 - Auswirkungen von EU HTA auf das AMNOG-Verfahren
Ausgabe 17, September 2023 - AMNOG: Finanzstabilisierung – neue Behandlungsparadigmen
Ausgabe 16, März 2023 - Weiterentwicklung des AMNOG mit Augenmaß und Evidenz
Ausgabe 15, September 2022 - Leitlinien - ihre rolle in AMNOG und Versorgung
Ausgabe 14, März 2022 - Patienten und Fachgesellschaft: Zusätzliche Expertise fürs AMNOG
Ausgabe 13, September 2021 - Digitale Gesundheitsdaten: Nutzen, Kosten, Governance
Ausgabe 12, März 2021 - Europäisches HTA Verfahren: Fortschritte und Fallstricke
Ausgabe 11, September 2020 - Welche (Zusatz-)Nutzen haben Registerdaten?
Ausgabe 10, April 2020 - Wege zur gezielten Therapie
Ausgabe 9, Oktober 2019 - Europäische Nutzenbewertung – Chancen und Risiken
Ausgabe 8, April 2019 - Arztinformation via Software: Orientierung oder Steuerung?
Ausgabe 7, August 2018 - Arztinformation via Software: Wege und Ziele
Ausgabe 6, März 2018 - Lücken in der Evidende - was leisten Registerdaten?
Ausgabe 5, November 2017 - AMNOG 2.0 - Informationsprobleme
Ausgabe 4, April 2017 - Adaptative Pathways - Chancen und Risiken
Ausgabe 3, September 2016 - Klinische Studien - welche Endpunkte zählen?
Ausgabe 2, März 2016 - Vier Jahre AMNOG - Diskurs und Impulse
Ausgabe 1, Juli 2015
 | Contact us for more information: info@r-connect.org |
